Formulation and evaluation of prazosin hydrochloride loaded solid lipid nanoparticles
PRAZOSIN HYDROCHLORIDE LOADED SOLID LIPID NANOPARTICLES
Abstract
Solid Lipid Nanoparticles (SLN) are rapidly developing field of nanotechnology with several potential application in drug delivery and research. Drugs having low aqueous solubility not only give low oral bioavailability but provide high inter-and intra subject variability. The purpose of the present study was to investigate the bioavailability enhancement of Prazosin Hydrochloride drug by formulating solid lipid nanoparticle. Prazosin Hydrochloride Drug is an antihypertensive drug with limited bioavailability so that solid lipid nanoparticle (SLN) is one of the approaches to improve bioavailability. SLN were prepared using glyceryl monostearate by hot homogenization followed by Solvent emulsification-ultrasonication. Prazosin Hydrochloride loaded SLN were characterized and optimized by parameters like particle size, zeta potential, XRD, DSC. Proposing Hydrochloride loaded SLN having the particle size 263.8±1.88 and entrapment efficiency 89.29±0.65% shows better bioavailability and optimum stability in studies. The SLN studies prepared using glyceryl mono stearate as a lipid and Polaxamer 407 as a polymer leads to improve bioavailability of the drug.
Keywords: Prazosin Hydrochloride, Solid Lipid Nanoparticles, Entrapment efficiency, DSC
Downloads
References
2. Shakeel. F, Ramadan W, Sheikh S, Solubility and Dissolution improvement of Aceclofenac using Different Nanocariers, J Bioequiv Availab, 2009; 1(2):039-043.
3. Ugurlu T, Nalbantoglu A, Sengel-Turk C, Development of solid lipid nanocarriers for oral delivery of candesertan cilexetil, Acta Poloniae. Pharmaceutica-Drug Research, 2016; 73(6):1631-1638.
4. Kaur I, Bhandari R, Bhandari S, Kakkar V, Potential of solid lipid nanoparticle in brain targeting, J of Cont Release, 2008; 127:97–109.
5. Okorie N, Mbah C, Studies on the Bioavailability Enhancement of Olmesartan Medoxomil: Solid Lipid Nanoparticle as Carrier System, J Chem Pharm Res, 2017; 9(8):64-72.
6. Raut I, Doijad R, Mohite S, Solid Lipid Nanoparticles: A Promising Drug Delivery System, Int J Pharm Sci Res, 2018; 9(3):862-71.
7. Ali J, Khar R, Ahuja A, Dosage form Design, 1st edition, Birla Publications Pvt. Ltd. 2009.
8. Sadiq A, Alla A, Rassol A, Formulation and Evaluation of silbinin loaded solid lipid nanoparticles for peroral use targeting lower part of gastrointestinal tract, Int J of Pharm and Pharm sci, 2014; 6(1):55-67.
9. Ekambaram P, Sathali A, Formulation and Evaluation of Solid Lipid Nanoparticles of Ramipril, J Young Pharmacist, 2011; 3:216-20.
10. Shelake S, Patil S, Patil S, Sangave S, Formulation and evaluation of fenofibrate-loaded nanoparticles by precipitation method, Indian J Pharm Sci, 2018; 80(3):420-427.
11. Verma S, Makkar D, Solid lipid nanoparticles: a comprehensive review, J chem. Pharm Res. 2016; 8(8):102-114.
12. Shelake S, Mhetre R, Patil S, Patil S, Khade V, Formulation and evaluation of Microspheres for nasal delivery of antihypertensive drug, Indian J Pharm Sci, 2018; 80(3):420-427.
13. Sangave P, Patil S, Patil S, Shelake S, Preparation and Evaluation of Mucoadhesive Nanoparticles of Rosuvastatin, Indian drugs, 2016; 53(10):21-26.
14. Mahajan A, Singh S, Kaur S, Agarwal A, Studies on Solubility Enhancement and In-vitro Dissolution Profile of Poorly Water Soluble Drug Atenolol Using Solid Dispersion Technique, Int. J Res Pharm Sci, 2013; 4(3):344-349.
15. Carsten R, Ulrike S, Aurora O, Kerstin T, Christian P, Rainer H, Application of novel solid lipid Nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT- Peptides In vitro and In vivo, J of pharm res 2004; 21(9):1662-1669.
16. Dingler A, Blum R, Niehus H, Mullar RH, Gohla, Solid lipid nanoparticles (SLNTM/Lipopearls TM) a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products, J of microencapsulation, 1999; 16(6):751-767.
17. Jifu H, Xinsheng F, Yanfang Z, J ianzhu W, Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design, Internationl of nanomedicine, 2011; 6:683.
18. Mahajan A, Singh S, Kaur S, Agarwal A, Studies on Solubility Enhancement and In-vitro Dissolution Profile of Poorly Water Soluble Drug Atenolol Using Solid Dispersion Technique, Int. J Res pharm Sci, 2013; 4(3):344-349.
19. Mullar R, Runge S, Raveli V, Thunemann A, Mehnert W, Souto E, Cyclosporine-loaded solid lipid Nanoparticles (SLN): Drug-lipid physicochemical interactions and characterization of drug incorporation, 2000; 68(3):535-544.
20. Deepthi S, Zaneb A, Reddy M, Damodaram A, Gupta K, Solid lipid nanoparticles of Irbesartan: preparation, characterization, optimization and pharmacokinetic studies, Brazilian J of Phar Sci, 2017; 53(1):15012-15020.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.